(a) Every individual or group health-insurance contract, plan, or policy that provides prescription coverage that is delivered, issued for delivery, amended or renewed in this state on or after January 1, 2017, shall provide coverage for at least one generic opioid antagonist and device. Prior authorization may be required for non-generic forms of opioid antagonists and devices.
Terms Used In Rhode Island General Laws 27-18-82
- Contract: A legal written agreement that becomes binding when signed.
- insured: as used in this chapter , shall not be construed as preventing a person other than the insured with a proper insurable interest from making application for and owning a policy covering the insured or from being entitled under the policy to any indemnities, benefits, and rights provided in the policy. See Rhode Island General Laws 27-18-7.
- United States: include the several states and the territories of the United States. See Rhode Island General Laws 43-3-8.
(b) As used in this section:
“Opioid antagonist” means naloxone hydrochloride and any other drug approved by the United States Food and Drug Administration for the treatment of opioid overdose.
(c) The coverage mandated by this section shall include generic opioid antagonists prescribed or dispensed via standing order or collaborative-practice agreement intended for use on patients other than the insured. Prior authorization may be required for non-generic forms of opioid antagonists and devices.
(d) Notwithstanding § 27-18-19, or any other provision to the contrary, this section shall apply to blanket or group polices of insurance.
(P.L. 2016, ch. 175, § 1; P.L. 2016, ch. 192, § 1.)